[HTML][HTML] Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
[PDF][PDF] Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis. Pharmaceutics 2023, 15, 577
RL Orfali, V Aoki - 2023 - pdfs.semanticscholar.org
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis
RL Orfali, V Aoki - Pharmaceutics, 2023 - pubmed.ncbi.nlm.nih.gov
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis.
RL Orfali, V Aoki - Pharmaceutics, 2023 - search.ebscohost.com
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis.
RL Orfali, V Aoki - Pharmaceutics, 2023 - europepmc.org
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis
RL Orfali, V Aoki - Pharmaceutics, 2023 - search.proquest.com
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis
RL ORFALI, V AOKI - Pharmaceutics, 2023 - observatorio.fm.usp.br
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
[HTML][HTML] Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis
RL Orfali, V Aoki - Pharmaceutics, 2023 - ncbi.nlm.nih.gov
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
[PDF][PDF] Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis. Pharmaceutics 2023, 15, 577
RL Orfali, V Aoki - 2023 - observatorio.fm.usp.br
Atopic dermatitis (AD), a pruritic, inflammatory chronic disease with multifactorial
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …
pathogenesis, has been a therapeutic challenge. Novel target treatments aim to reduce not …